Geode Capital Management
INMB icon

Geode Capital Management’s INmune Bio INMB Stock Holding History

Geode Capital Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$559K Buy
494,969
+53,319
+12% +$76K ﹤0.01% 3546
2025
Q4 		$689K Sell
441,650
-27,790
-6% -$49.6K ﹤0.01% 3484
2025
Q3 		$972K Buy
469,440
+79,509
+20% +$182K ﹤0.01% 3387
2025
Q2 		$901K Buy
389,931
+25,069
+7% +$184K ﹤0.01% 3358
2025
Q1 		$2.85M Buy
364,862
+1,260
+0.3% +$10K ﹤0.01% 2914
2024
Q4 		$1.7M Buy
363,602
+19,136
+6% +$99.8K ﹤0.01% 3189
2024
Q3 		$1.86M Buy
344,466
+21,262
+7% +$151K ﹤0.01% 3150
2024
Q2 		$2.85M Buy
323,204
+152,402
+89% +$1.5M ﹤0.01% 3008
2024
Q1 		$2.01M Buy
170,802
+762
+0.4% +$9.21K ﹤0.01% 3107
2023
Q4 		$1.91M Buy
170,040
+2,937
+2% +$24.6K ﹤0.01% 3114
2023
Q3 		$1.14M Buy
167,103
+12,423
+8% +$103K ﹤0.01% 3267
2023
Q2 		$1.4M Buy
154,680
+11,023
+8% +$88.5K ﹤0.01% 3226
2023
Q1 		$928K Buy
143,657
+660
+0.5% +$5.32K ﹤0.01% 3382
2022
Q4 		$906K Buy
142,997
+3,391
+2% +$24.1K ﹤0.01% 3386
2022
Q3 		$865K Buy
139,606
+1,382
+1% +$12.1K ﹤0.01% 3467
2022
Q2 		$1.22M Buy
138,224
+10,695
+8% +$79.6K ﹤0.01% 3332
2022
Q1 		$1.07M Buy
127,529
+9,259
+8% +$83.2K ﹤0.01% 3588
2021
Q4 		$1.21M Buy
118,270
+28,663
+32% +$424K ﹤0.01% 3624
2021
Q3 		$1.74M Buy
89,607
+15,813
+21% +$305K ﹤0.01% 3419
2021
Q2 		$1.3M Buy
73,794
+12,957
+21% +$175K ﹤0.01% 3473
2021
Q1 		$722K Buy
60,837
+27,182
+81% +$489K ﹤0.01% 3682
2020
Q4 		$579K Buy
33,655
+3,632
+12% +$34.2K ﹤0.01% 3545
2020
Q3 		$309K Buy
+30,023
New +$305K ﹤0.01% 3586

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

Geode Capital Management's INMB Position: Q1 2026 in Review

Geode Capital Management increased its INmune Bio (INMB) stake by 12% in Q1 2026, buying an estimated $76K and bringing the position to 494,969 shares worth $559K. The position accounts for ﹤0.01% of the portfolio, ranked #3546.

Geode Capital Management first reported a position in INMB in Q3 2020 and has held it in 23 quarters since. The position peaked at $2.85M in Q2 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • Geode Capital Management held 494,969 shares of INmune Bio worth $559K as of Q1 2026.
  • Geode Capital Management bought 53,319 INmune Bio shares in Q1 2026, an estimated $76K.
  • INmune Bio made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3546 holding.
  • Geode Capital Management first reported a position in INmune Bio in Q3 2020 and has held it in 23 quarters since.
  • Geode Capital Management's INmune Bio position peaked at $2.85M in Q2 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.